Antibody-Drug Conjugate and Its Application on Lung Cancer
DOI:
https://doi.org/10.61173/kkmdc990Keywords:
Antibody-drug conjugates, monoclonal anti-body, non-small cell lung cancerAbstract
Antibody-drug conjugates (ADCs) represent a promising class of anticancer therapeutics, comprising a monoclonal antibody (mAb) linked to a cytotoxin via a specialized linker. Currently, 15 ADCs have received FDA approval, with numerous others undergoing clinical trials. Despite their potential, ADCs have shown limited application primarily in specific cancer types such as adenocarcinoma, and their efficacy in other cancers like non-small cell lung cancer (NSCLC) remains under exploration. This paper reviews the history of ADC development and delves into the mechanisms underlying their function. It provides a detailed analysis of the various components of ADCs—antibodies, linkers, and cytotoxins—and how their selection impacts the overall efficacy and safety of the drug. Specific targets, such as HER2, and corresponding ADCs are also discussed. Additionally, the challenges associated with ADC application, including poor target specificity and the risk of severe off-target effects, are highlighted as critical areas for ongoing research and development.
References
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a Cancer Journal for Clinicians, 2024, 74(3): 229-263.
[2] Yee S S, et al. Taccalonolide Microtubule Stabilizers. Progress in the Chemistry of Organic Natural Products, 2020, 112: 183-206.
[3] Taylor P C, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews Immunology, 2021, 21(6): 382-393.
[4] Fu Z, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2022, 7(1): 93.
[5] Passaro A, Jänne P A, Peters S. Antibody-Drug conjugates in lung cancer: Recent advances and implementing strategies. Journal of Clinical Oncology, 2023, 41(21): 3747-3761.
[6] Rosner S, Valdivia A, Hoe H J, et al. Antibody-Drug conjugates for lung cancer: Payloads and progress. American Society of Clinical Oncology Educational Book, 2023, 43.
[7] Tan A C, et al. Clinical and genomic features of HER2 ExON 20 insertion mutations and characterization of HER2 expression by immunohistochemistry in East Asian Non–Small-Cell lung cancer. JCO Precision Oncology, 2022, 6.
[8] Scharpenseel H, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Scientific Reports, 2019, 9: 7406. Dean&Francis Jason Yu
[9] Stepan L P, et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. The Journal of Histochemistry and Cytochemistry, 2011, 59(7): 701-710.
[10] Zhao P, et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharmaceutica Sinica. B, 2020, 10(9): 1589-1600.
[11] Powell C A, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open, 2022, 7(4): 100554.
[12] Kovtun Y V, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Research, 2006, 66(6): 3214-3221.
[13] Staudacher A H, Brown M P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?. British Journal of Cancer, 2017, 117(12): 1736-1742.
[14] Cleavable vs. Non-Cleavable Linkers. (2021-07-21) [2024-08-31]. https://broadpharm.com/blog/cleavable-vs-noncleavable-linkers.
[15] Hafeez U, Parakh S, Gan H K, et al. Antibody-Drug Conjugates for Cancer Therapy. Molecules, 2020, 25(20): 4764.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
